China Pharma Holdings, Inc.
CPHIHealthcare|Drug Manufacturers - Specialty & Generic|CN
$0.57
+0.04 (+7.53%)
Cash / Share
$0.07
Financials
Financial Snapshot
Market Cap
$24.5M
Enterprise Value
$28.0M
Revenue (TTM)
$3.9M
Net Income (TTM)
-$4.5M
Cash & Investments
$304.9K
Net Cash
-$3.4M
Free Cash Flow (TTM)
-$219.5K
Operating CF (TTM)
-$140.5K
Debt/Equity
0.10
Cash Runway & Burn Rate
Cash on Hand
$304.9K
Quarterly Burn
$35.1K
Monthly Burn
$11.7K
Est. Runway
~8.7 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $2.7M | $2.0M | $1.2M | $1.1M | $957.7K | $4.9M | $2.0M | $1.4M | $626.9K | $345.1K | $304.9K | |
| Operating Cash Flow | $2.9M | $841.2K | $1.3M | $608.3K | -$42.3K | -$249.8K | -$409.5K | -$699.7K | -$466.4K | $148.3K | -$140.5K | |
| Free Cash Flow | $2.7M | $704.7K | $1.2M | $472.3K | -$909.6K | -$687.9K | -$811.5K | -$711.2K | -$758.1K | $11.0K | -$219.5K | |
| Capital Expenditure | -$193.4K | -$136.5K | -$51.1K | -$136.0K | -$867.3K | -$438.1K | -$402.0K | -$11.5K | -$291.7K | -$137.3K | -$79.0K | |
| Financing Cash Flow | -$6.0M | -$1.5M | -$2.0M | -$1.7M | $624.2K | $4.6M | -$1.8M | $73.1K | $27.4K | -$294.0K | -$154.0K |
R&D Spending
R&D (TTM)
$333.3K
R&D Intensity
8.5%
R&D Growth vs Prior
+18.6%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $15.6M | $13.2M | $12.3M | $10.9M | $10.9M | $9.6M | $8.1M | $7.0M | $4.5M | $4.1M | $3.9M | |
| R&D Expense | $366.0K | $90.5K | $172.4K | $229.6K | $378.0K | $319.0K | $185.9K | $240.1K | $283.9K | $280.9K | $333.3K | |
| R&D % of Revenue | 2.4% | 0.7% | 1.4% | 2.1% | 3.5% | 3.3% | 2.3% | 3.4% | 6.3% | 6.8% | 8.5% | |
| SG&A | $6.3M | $5.5M | $5.2M | $4.6M | $4.0M | $3.1M | $3.0M | $2.2M | $2.3M | $2.8M | $3.7M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $15.6M | $13.2M | $12.3M | $10.9M | $10.9M | $9.6M | $8.1M | $7.0M | $4.5M | $4.1M | $3.9M | |
| Cost of Revenue | $12.4M | $10.7M | $10.4M | $9.4M | $8.9M | $9.3M | $8.6M | $7.3M | $6.5M | $4.3M | $4.3M | |
| Gross Profit | $3.2M | $2.5M | $2.0M | $1.5M | $2.0M | $349.3K | -$493.9K | -$281.1K | -$2.0M | -$131.9K | -$365.1K | |
| R&D | $366.0K | $90.5K | $172.4K | $229.6K | $378.0K | $319.0K | $185.9K | $240.1K | $283.9K | $280.9K | $333.3K | |
| SG&A | $6.3M | $5.5M | $5.2M | $4.6M | $4.0M | $3.1M | $3.0M | $2.2M | $2.3M | $2.8M | $3.7M | |
| Operating Income | -$4.2M | -$4.5M | -$4.0M | -$3.4M | -$2.6M | -$2.9M | -$3.5M | -$2.8M | -$4.6M | -$3.1M | -$4.4M | |
| Interest Expense | $849.6K | $539.3K | $451.3K | $321.7K | $294.2K | $542.0K | $434.6K | $333.6K | $154.1K | $102.0K | $99.0K | |
| Pretax Income | -$8.9M | -$19.2M | -$10.9M | -$20.7M | -$2.9M | -$3.4M | -$4.0M | -$3.1M | -$4.7M | -$3.2M | -$4.5M | |
| Net Income | -$9.2M | -$19.3M | -$10.8M | -$20.7M | -$2.9M | -$3.4M | -$4.0M | -$3.1M | -$4.7M | -$3.2M | -$4.5M | |
| EPS (Diluted) | -2.11 | -4.42 | -2.47 | -4.82 | -0.72 | -0.85 | -1.94 | -0.29 | -0.27 | -0.74 | -1.01 | |
| EBITDA | -$4.9M | -$15.3M | -$7.2M | -$17.5M | $106.9K | $230.3K | -$837.7K | $8.4K | -$2.0M | -$1.5M | -$1.3M | |
| Shares Out. (M) | 4.61 | 4.61 | 4.61 | 4.61 | 4.61 | 4.61 | 5.26 | 10.60 | 17.46 | 4.29 | 4.29 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.7M | $2.0M | $1.2M | $1.1M | $957.7K | $4.9M | $2.0M | $1.4M | $626.9K | $345.1K | $304.9K | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $17.5M | $12.3M | $8.7M | $5.6M | $5.3M | $9.1M | $6.0M | $6.0M | $3.3M | $2.3M | $2.0M | |
| Total Assets | $78.5M | $60.0M | $45.4M | $22.2M | $21.1M | $22.6M | $17.8M | $16.5M | $14.9M | $31.0M | $44.7M | |
| Total Current Liabilities | $10.4M | $9.2M | $10.1M | $10.0M | $11.4M | $10.5M | $12.7M | $6.8M | $5.0M | $7.4M | $7.7M | |
| Long-Term Debt | $8.6M | $6.9M | $4.4M | $2.2M | $904.2K | $5.3M | $0.00 | $1.4M | $1.4M | $0.00 | $0.00 | |
| Total Liabilities | $19.6M | $16.9M | $15.2M | $13.0M | $13.1M | $16.6M | $13.5M | $9.0M | $7.1M | $8.3M | $8.5M | |
| Stockholders' Equity | $58.9M | $43.1M | $30.2M | $9.2M | $8.0M | $6.0M | $4.3M | $7.5M | $7.7M | $22.7M | $36.2M | |
| Retained Earnings | $24.8M | $5.5M | -$5.3M | -$26.0M | -$28.8M | -$32.2M | -$36.2M | -$39.3M | -$44.0M | -$47.2M | -$49.8M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $2.9M | $841.2K | $1.3M | $608.3K | -$42.3K | -$249.8K | -$409.5K | -$699.7K | -$466.4K | $148.3K | -$140.5K | |
| Capital Expenditure | -$193.4K | -$136.5K | -$51.1K | -$136.0K | -$867.3K | -$438.1K | -$402.0K | -$11.5K | -$291.7K | -$137.3K | -$79.0K | |
| Free Cash Flow | $2.7M | $704.7K | $1.2M | $472.3K | -$909.6K | -$687.9K | -$811.5K | -$711.2K | -$758.1K | $11.0K | -$219.5K | |
| Investing Cash Flow | -$193.4K | -$136.5K | -$51.1K | -$136.0K | -$867.3K | -$438.1K | -$402.0K | -$11.5K | -$291.7K | -$137.3K | -$79.0K | |
| Financing Cash Flow | -$6.0M | -$1.5M | -$2.0M | -$1.7M | $624.2K | $4.6M | -$1.8M | $73.1K | $27.4K | -$294.0K | -$154.0K | |
| Issuance of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | -$6.0M | -$1.5M | -$2.0M | -$1.7M | $624.2K | $4.6M | -$1.5M | $73.1K | $27.4K | -$294.0K | -$154.0K | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $15.2K | $78.3K | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Change in Cash | -$3.6M | -$635.6K | -$843.6K | -$1.3M | -$227.2K | $3.9M | -$2.8M | -$606.1K | -$797.0K | -$281.8K | -$320.2K |
Dilution Tracker
Shares Outstanding
43M
5-Year Share Growth
-7.0%
Stock Issuance (TTM)
$0.00
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 4.61 | 4.61 | 4.61 | 4.61 | 4.61 | 4.61 | 5.26 | 10.60 | 17.46 | 4.29 | 4.29 | |
| Change vs Prior % | — | 0.0% | 0.0% | 0.0% | 0.0% | -0.0% | 14.0% | 101.6% | 64.8% | -75.4% | 0.0% | |
| Stock Issuance | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $15.2K | $78.3K | $0.00 | $0.00 | $0.00 | $0.00 |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 20.7% | 18.7% | 16.0% | 13.6% | 18.0% | 3.6% | -6.1% | -4.0% | -43.8% | -3.2% | -9.3% | |
| Operating Margin % | -26.9% | -34.0% | -32.2% | -31.0% | -23.7% | -29.7% | -43.8% | -39.2% | -101.3% | -74.5% | -111.8% | |
| Net Margin % | -59.0% | -145.9% | -87.2% | -189.5% | -26.4% | -35.3% | -49.0% | -43.9% | -104.6% | -76.9% | -114.3% | |
| EBITDA Margin % | -31.8% | -116.0% | -58.0% | -159.8% | 1.0% | 2.4% | -10.3% | 0.1% | -43.4% | -36.3% | -33.8% | |
| FCF Margin % | 17.4% | 5.3% | 9.8% | 4.3% | -8.4% | -7.1% | -10.0% | -10.1% | -16.7% | 0.3% | -5.6% | |
| ROE % | -15.6% | -44.8% | -35.6% | -224.1% | -35.8% | -56.5% | -92.6% | -41.3% | -61.1% | -14.0% | -17.1% | |
| ROA % | -11.7% | -32.2% | -23.7% | -93.1% | -13.6% | -15.0% | -22.3% | -18.7% | -31.8% | -10.3% | -10.0% | |
| ROIC % | -5.9% | -8.4% | -10.1% | -20.4% | -15.9% | -14.8% | -25.7% | -21.4% | -38.0% | -11.3% | -10.8% | |
| R&D / Revenue % | 2.4% | 0.7% | 1.4% | 2.1% | 3.5% | 3.3% | 2.3% | 3.4% | 6.3% | 6.8% | 8.5% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -23.5% | -15.1% | -6.7% | -11.4% | -0.5% | -11.3% | -15.9% | -13.5% | -35.4% | -8.5% | |
| Gross Profit | 119.8% | -23.3% | -20.0% | -24.9% | 31.8% | -82.1% | -241.4% | 43.1% | -606.4% | 93.4% | |
| Operating Income | 70.5% | -7.2% | 11.7% | 14.6% | 23.9% | -10.9% | -24.1% | 22.5% | -66.8% | 32.7% | |
| Net Income | 40.4% | -109.9% | 44.2% | -92.6% | 86.2% | -18.6% | -16.9% | 22.5% | -53.8% | 32.7% | |
| EPS (Diluted) | 40.4% | -109.5% | 44.1% | -95.1% | 85.1% | -18.1% | -128.2% | 85.1% | 6.9% | -174.1% | |
| Operating Cash Flow | -13.6% | -70.9% | 49.4% | -51.6% | -106.9% | -491.2% | -63.9% | -70.8% | 33.3% | 131.8% | |
| Free Cash Flow | 162.2% | -73.9% | 71.1% | -60.8% | -292.6% | 24.4% | -18.0% | 12.4% | -6.6% | 101.5% | |
| R&D Expense | -62.0% | -75.3% | 90.5% | 33.2% | 64.6% | -15.6% | -41.7% | 29.2% | 18.3% | -1.1% | |
| SG&A Expense | 1.8% | -13.0% | -5.7% | -10.1% | -13.0% | -22.1% | -5.8% | -24.2% | 3.0% | 22.2% | |
| Total Assets | -19.2% | -23.6% | -24.3% | -51.0% | -5.0% | 7.3% | -21.5% | -7.4% | -9.6% | 108.2% | |
| Book Value / Share | -18.9% | -26.9% | -29.9% | -69.4% | -13.3% | -24.8% | -37.4% | -13.8% | -36.9% | 1094.5% | |
| Debt | -34.1% | -11.1% | -21.3% | -15.3% | 12.2% | 68.1% | -29.9% | -47.1% | -22.5% | 8.2% | |
| Diluted Shares | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -0.0% | 14.0% | 101.6% | 64.8% | -75.4% |
Valuation
P/E (TTM)At Loss
P/S6.26
10Y Low / Med / High1.25 / 38.51 / 115.44
P/B0.07
10Y Low / Med / High0.23 / 19.66 / 184.97
EV/EBITDAAt Loss
10Y Low / Med / High4865.43 / 7983.02 / 9683.42
EV/Revenue7.14
10Y Low / Med / High2.11 / 39.06 / 116.23
P/FCFAt Loss
10Y Low / Med / High221.91 / 492.34 / 1156.38
Intrinsic Value Models (per share)
Cash / Share
$0.07
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -61.61 | -19.86 | -52.11 | -24.56 | -309.58 | -283.88 | -24.74 | -20.86 | -8.63 | -1.64 | -0.56 | |
| P/S Ratio | 38.51 | 30.65 | 48.15 | 50.00 | 94.62 | 115.44 | 31.14 | 9.15 | 8.98 | 1.25 | 6.26 | |
| P/B Ratio | 10.18 | 9.40 | 19.66 | 59.12 | 128.46 | 184.97 | 58.82 | 8.60 | 5.25 | 0.23 | 0.07 | |
| EV/EBITDA | -122.94 | -26.95 | -83.96 | -31.61 | 9683.42 | 4865.43 | -309.25 | 7983.02 | -22.23 | -5.80 | -21.12 | |
| EV/Revenue | 39.06 | 31.25 | 48.68 | 50.51 | 95.22 | 116.23 | 31.97 | 9.60 | 9.64 | 2.11 | 7.14 |
Analyst Estimates & Quality
Altman Z-Score
-0.22
Distress
Piotroski F-Score
3
Weak
Revenue Segments
By Product
| Segment | 2020 | 2021 |
|---|---|---|
| COVID 19 Testers | $1.7M | — |
| Domestic Pharmaceuticals | $9.1M | — |
| DomesticPharmaceuticalsMember | — | $9.6M |